Plasma VL was measured quantitatively with the Roche Amplicor version 1.5 ultrasensitive assay with a lower limit of quantification of 50 copies/mL (Roche Diagnostics), before replacement with the COBAS TaqMan HIV-1 Test version 2.0 (Roche Diagnostics) with a lower limit of quantification of 20 copies/mL. Plasma VL was measured at the time of study enrollment, every 2 weeks from the date of enrollment through week 4 of ART, every 4 weeks from week 4 through week 24 of ART, and every 12 weeks thereafter. Single-copy HIV-1 RNA levels were measured retrospectively using ultrasensitive hybrid real-time/digital PCR, as previously described (51 (link), 52 (link)). The AUC was calculated by adding the AUC measured in the study starting at ART initiation and the estimated AUC at each AHI stage derived from the VL trendline in untreated AHI (23 (link), 30 (link)).
Mitchell J.L., Pollara J., Dietze K., Edwards R.W., Nohara J., N’guessan K.F., Zemil M., Buranapraditkun S., Takata H., Li Y., Muir R., Kroon E., Pinyakorn S., Jha S., Manasnayakorn S., Chottanapund S., Thantiworasit P., Prueksakaew P., Ratnaratorn N., Nuntapinit B., Fox L., Tovanabutra S., Paquin-Proulx D., Wieczorek L., Polonis V.R., Maldarelli F., Haddad E.K., Phanuphak P., Sacdalan C.P., Rolland M., Phanuphak N., Ananworanich J., Vasan S., Ferrari G, & Trautmann L. (2022). Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. The Journal of Clinical Investigation, 132(1), e150937.
Assay Diagnostics Hiv 1 Hiv 2 Hiv test HybridPlasma Real time pcr Time
Corresponding Organization :
Other organizations :
Oregon Health & Science University, Walter Reed Army Institute of Research, Henry M. Jackson Foundation, Duke Medical Center, Chulalongkorn University, Drexel University, HIV Netherlands Australia Thailand Research Collaboration, Bamrasnaradura Infectious Diseases Institute, Armed Forces Research Institute of Medical Science, National Institute of Allergy and Infectious Diseases, National Cancer Institute, Amsterdam Institute for Global Health and Development, University of Amsterdam
Replacement of Roche Amplicor version 1.5 ultrasensitive assay with COBAS TaqMan HIV-1 Test version 2.0
dependent variables
Plasma viral load (VL) measured quantitatively
Single-copy HIV-1 RNA levels
control variables
Lower limit of quantification for Roche Amplicor version 1.5 ultrasensitive assay (50 copies/mL)
Lower limit of quantification for COBAS TaqMan HIV-1 Test version 2.0 (20 copies/mL)
Timing of plasma VL measurements (at enrollment, every 2 weeks through week 4, every 4 weeks from week 4 through week 24, and every 12 weeks thereafter)
positive controls
Not specified
negative controls
Not specified
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to
get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
